The Effect of Rituximab on Antiphospholipid Titers in Patients with Antiphospholipid Syndrome
Open Access
- 5 July 2023
- journal article
- letter
- Published by Georg Thieme Verlag KG in TH Open
- Vol. 07 (03) , e191-e194
Abstract
Rituximab in patients with antiphospholipid syndrome (APS) is mostly used for treating noncriteria APS manifestations such as thrombocytopenia, and is not a first- or second-line treatment for management of thrombosis. However, at times rituximab is used empirically as adjunct treatment in patients with recurrent thrombosis occurring in spite of anticoagulant therapy (i.e., anticoagulation failure) when combinations of increased anticoagulation intensity, addition of antiplatelet therapy, and reduction of all thrombotic risk factors fail to prevent recurrent thrombosis.[1] [2] Knowledge of its effect on the naturally fluctuating antiphospholipid antibody (APLA) titers is, however, limited. We sought to determine the effect of rituximab on decreasing the magnitude and type of APLA in patients with thrombotic APS. K.Y. designed the study, collected the data, and was involved in the data analysis, and wrote the manuscript. S.M. designed the study and oversaw the manuscript, data collection, and analysis and manuscript writing. H.H. performed the statistical analysis; A.D. oversaw the statistical analysis. Received: 13 January 2023 Accepted: 21 April 2023 Article published online: 05 July 2023 © 2023. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. (https://creativecommons.org/licenses/by/4.0/) Georg Thieme Verlag KG Rüdigerstraße 14, 70469 Stuttgart, GermanyKeywords
This publication has 14 references indexed in Scilit:
- Rituximab use in the catastrophic antiphospholipid syndrome: Descriptive analysis of the CAPS registry patients receiving rituximabAutoimmunity Reviews, 2013
- A pilot open‐label phase II trial of rituximab for non‐criteria manifestations of antiphospholipid syndromeArthritis & Rheumatism, 2012
- Treatment-induced downregulation of antiphospholipid antibodies: effect of rituximab alone on clinical and laboratory features of antiphospholipid syndromeLupus, 2011
- Effective treatment of antiphospholipid syndrome with plasmapheresis and rituximab.2010
- Use of Rituximab in the Antiphospholipid SyndromeCurrent Rheumatology Reports, 2010
- Clinical Improvement in Antiphospholipid Syndrome After Rituximab TherapyJCR: Journal of Clinical Rheumatology, 2008
- A Comparison of Lupus Anticoagulant–Positive Patients With Clinical Picture of Antiphospholipid Syndrome and Those WithoutArteriosclerosis, Thrombosis, and Vascular Biology, 2007
- Limited effect of rituximab on thrombocytopaenia and anticardiolipin antibodies in a patient with primary antiphospholipid syndromeAnnals of Hematology, 2006
- ‘Cure’ of life‐threatening antiphospholipid syndrome with rituximabInternal Medicine Journal, 2006
- Long-term remission from life-threatening hypercoagulable state associated with lupus anticoagulant (LA) following rituximab therapyAmerican Journal of Hematology, 2005